ID
42317
Beskrivning
Study ID: 108708 Clinical Study ID: 108708 Study Title: A phase IIb, controlled, randomized, multicentre, observer blinded study to evaluate the immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 compared to a second dose of FluarixTM (GlaxoSmithKline Biologicals) administered intramuscularly in elderly >= 60 years previously vaccinated in FLU-LD-002 clinical trial Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00385840 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Influenza Vaccine GSK1247446A Trade Name: FluarixTM Study Indication: Influenza
Nyckelord
Versioner (1)
- 2021-05-29 2021-05-29 -
Rättsinnehavare
GlaxoSmithKline
Uppladdad den
29 maj 2021
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Immunogenicity, safety and reactogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with AS03 NCT00385840
Visit 1, Day 0 Vaccination: Informed Consent; Demographics; Randomisation
Similar models
Visit 1, Day 0 Vaccination: Informed Consent; Demographics; Randomisation
C0019994 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0019994 (UMLS CUI [1,2])
C1522541 (UMLS CUI-2)
C0600091 (UMLS CUI [1,2])